Natco Pharma Ltd (NATCOPHARM) Q3FY25 Concall Summary - Dec-2024 Qtr
Performance Overview
- Natco Pharma reported weaker performance in the December 2024 quarter.
- Consolidated total revenue was Rs 651.1 crore, down from Rs 795.6 crore in the same period last year.
- Net profit was Rs 132.4 crore, compared to Rs 212.7 crore last year.
- The decline is primarily attributed to lower contribution from the export formulation business, specifically the absence of Revlimid sales.
- The company anticipates a return to healthy growth in the upcoming quarter, driven by a new Revlimid allocation.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.